Rinvoq Psoriatic Arthritis Drug Insight And Market Forecast

“RINVOQ Drug Insight and Market Forecast – 2032” report provides comprehensive insights about RINVOQ for Psoriatic Arthritis (PsA) in the seven major markets. A detailed picture of the RINVOQ for psoriatic arthritis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the RINVOQ for psoriatic arthritis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the RINVOQ market forecast analysis for psoriatic arthritis in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in psoriatic arthritis.

Drug Summary

RINVOQ is the first oral, once-daily, selective, and reversible JAK inhibitor approved for three adult rheumatic indications in the EU – rheumatoid arthritis (RA), PsA, and ankylosing spondylitis – the approved dose for RINVOQ in RA is 15 mg. It is being developed to treat immune-mediated inflammatory diseases.

RINVOQ received US FDA approval for adult patients with moderately to severely active RA who have had an inadequate response or intolerance to MTX. RINVOQ is approved by the European Commission for the treatment of adult patients with moderate to severely active RA who have responded inadequately to, or who are intolerant to one or more DMARDs; for the treatment of active PsA in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs; and for the treatment of active AS in adult patients who have responded inadequately to conventional therapy. The approved dose for RINVOQ in these indications is 15 mg.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the RINVOQ description, mechanism of action, dosage and administration, research and development activities in psoriatic arthritis.
• Elaborated details on RINVOQ regulatory milestones and other development activities have been provided in this report.
• The report also highlights the RINVOQ research and development activities in psoriatic arthritis across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around RINVOQ.
• The report contains forecasted sales of for psoriatic arthritis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for psoriatic arthritis.
• The report also features the SWOT analysis with analyst views for RINVOQ in psoriatic arthritis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

RINVOQ Analytical Perspective by DelveInsight

In-depth RINVOQ Market Assessment

This report provides a detailed market assessment of RINVOQ for psoriatic arthritis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

RINVOQ Clinical Assessment

The report provides the clinical trials information of RINVOQ for psoriatic arthritis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for psoriatic arthritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence RINVOQ dominance.
• Other emerging products for psoriatic arthritis are expected to give tough market competition to RINVOQ and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of RINVOQ in psoriatic arthritis.
• Our in-depth analysis of the forecasted sales data of RINVOQ from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the RINVOQ in psoriatic arthritis.

Key Questions

• What is the product type, route of administration and mechanism of action of RINVOQ?
• What is the clinical trial status of the study related to RINVOQ in psoriatic arthritis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the RINVOQ development?
• What are the key designations that have been granted to RINVOQ for psoriatic arthritis?
• What is the forecasted market scenario of RINVOQ for psoriatic arthritis?
• What are the forecasted sales of RINVOQ in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to RINVOQ for psoriatic arthritis?
• Which are the late-stage emerging therapies under development for the treatment of psoriatic arthritis?